Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
| Technology Name (St. Jude Reference #) | Janus-Associated Kinase (JAK) (SJ-93-0001) |
| Description | JAKs, together with signal transducers and activators of transcription (STATs), provide a rapid signaling pathway for cytokines and are involved in various cellular functions, including proliferation, growth, hematopoiesis, and immune response. Their roles in pathologies ranging from cancer to immune deficiencies have made them popular drug targets. JAK3, in particular, has been shown to be an anti-inflammatory drug target. St. Jude's patent portfolio covers methods for regulating JAK activity, assays for identifying JAK regulators, and DNA that encodes JAK3 and fragments thereof. This technology can be used as a tool to identify inhibitors for the treatment of some hematological tumors and leukemias, myeloproliferative disorders and immune diseases. |
| Keywords | Kinase, anti-inflammatory drug target, cancer drug target |
| Granted Patents or Published Applications | U.S. Patent Nos. 5,728,536; 6,136,595; 6,210,654 and 6,969,760 |
| Related Scientific References | Wilks AF; The JAK kinases: not just another kinase drug discovery target; Semin Cell Dev Biol. 2008 Aug; 19 (4):319-28. |
| Licensing Opportunities | We are seeking nonexclusive licensing opportunities in all fields. |
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: September 2010
